Tikun Olam-Cannbit Pharmaceuticals Ltd

TASE:TKUN Stock Report

Market Cap: ₪27.3m

Tikun Olam-Cannbit Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Tikun Olam-Cannbit Pharmaceuticals's earnings have been declining at an average annual rate of -32.8%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been growing at an average rate of 36% per year.

Key information

-32.8%

Earnings growth rate

-2.7%

EPS growth rate

Pharmaceuticals Industry Growth35.1%
Revenue growth rate36.0%
Return on equity-859.2%
Net Margin-117.6%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Tikun Olam-Cannbit Pharmaceuticals Ltd's (TLV:TKUN) Popularity With Investors Under Threat As Stock Sinks 26%

Dec 02
Tikun Olam-Cannbit Pharmaceuticals Ltd's (TLV:TKUN) Popularity With Investors Under Threat As Stock Sinks 26%

Health Check: How Prudently Does Tikun Olam-Cannbit Pharmaceuticals (TLV:TKUN) Use Debt?

Oct 23
Health Check: How Prudently Does Tikun Olam-Cannbit Pharmaceuticals (TLV:TKUN) Use Debt?

Tikun Olam-Cannbit Pharmaceuticals (TLV:TKUN) Has Debt But No Earnings; Should You Worry?

Jun 21
Tikun Olam-Cannbit Pharmaceuticals (TLV:TKUN) Has Debt But No Earnings; Should You Worry?

Tikun Olam-Cannbit Pharmaceuticals Ltd (TLV:TKUN) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Apr 28
Tikun Olam-Cannbit Pharmaceuticals Ltd (TLV:TKUN) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Risks To Shareholder Returns Are Elevated At These Prices For Tikun Olam-Cannbit Pharmaceuticals Ltd (TLV:TKUN)

Jul 21
Risks To Shareholder Returns Are Elevated At These Prices For Tikun Olam-Cannbit Pharmaceuticals Ltd (TLV:TKUN)

Would Tikun Olam-Cannbit Pharmaceuticals (TLV:TKUN) Be Better Off With Less Debt?

Oct 03
Would Tikun Olam-Cannbit Pharmaceuticals (TLV:TKUN) Be Better Off With Less Debt?

Is Tikun Olam-Cannbit Pharmaceuticals (TLV:TKUN) Weighed On By Its Debt Load?

Jun 03
Is Tikun Olam-Cannbit Pharmaceuticals (TLV:TKUN) Weighed On By Its Debt Load?

Tikun Olam-Cannbit Pharmaceuticals (TLV:TKUN) Is Carrying A Fair Bit Of Debt

Oct 17
Tikun Olam-Cannbit Pharmaceuticals (TLV:TKUN) Is Carrying A Fair Bit Of Debt

Is Tikun Olam - Cannbit Pharmaceuticals (TLV:TKUN) Using Debt Sensibly?

May 19
Is Tikun Olam - Cannbit Pharmaceuticals (TLV:TKUN) Using Debt Sensibly?

Shareholders Of Tikun Olam - Cannbit Pharmaceuticals (TLV:TKUN) Must Be Happy With Their 135% Total Return

Mar 19
Shareholders Of Tikun Olam - Cannbit Pharmaceuticals (TLV:TKUN) Must Be Happy With Their 135% Total Return

How Much Did Tikun Olam - Cannbit Pharmaceuticals'(TLV:TKUN) Shareholders Earn From Share Price Movements Over The Last Five Years?

Dec 02
How Much Did Tikun Olam - Cannbit Pharmaceuticals'(TLV:TKUN) Shareholders Earn From Share Price Movements Over The Last Five Years?

Revenue & Expenses Breakdown

How Tikun Olam-Cannbit Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

TASE:TKUN Revenue, expenses and earnings (ILS Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2443-50191
31 Mar 2443-69213
31 Dec 2344-89234
30 Sep 2347-98245
30 Jun 2351-107257
31 Mar 2350-77256
31 Dec 2249-48245
30 Sep 2245-38246
30 Jun 2241-27246
31 Mar 2239-30267
31 Dec 2137-33287
30 Sep 2132-34286
30 Jun 2128-35294
31 Mar 2125-34293
31 Dec 2022-33292
30 Sep 2016-27272
30 Jun 2011-20191
31 Mar 205-16131
31 Dec 190-1191
30 Sep 190-1750
30 Jun 190-2430
31 Mar 190-2320
31 Dec 180-2110
31 Dec 170000
31 Dec 160-110
31 Dec 150-330
30 Sep 140-520
31 Dec 133-1320

Quality Earnings: TKUN is currently unprofitable.

Growing Profit Margin: TKUN is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: TKUN is unprofitable, and losses have increased over the past 5 years at a rate of 32.8% per year.

Accelerating Growth: Unable to compare TKUN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TKUN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (6.6%).


Return on Equity

High ROE: TKUN has a negative Return on Equity (-859.16%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies